Oryx Pharmaceuticals to Market CNS Drugs in Canada
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 28 (Table of Contents)
Published: 2 Sep-2002
DOI: 10.3833/pdr.v2002.i28.1014 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Oryx Pharmaceuticals acquired the Canadian rights from Novartis Pharmaceuticals for central nervous system products such as Anafranil® (clomipramine) for treating depression and obsessive compulsive disorder, and Restoril® (temazipam) for short-term insomnia...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS